FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978293971> ?p ?o ?g. }

• W1978293971 endingPage "980" @default.
• W1978293971 startingPage "974" @default.
• W1978293971 abstract "Study Objective As data that prompted a 2009 labeling change detailing contraindications, precautions, and dosing recommendations for the first branded colchicine product were limited to case reports of myotoxicity and blood dyscrasias ascribed to the drug, we sought to quantify the association of colchicine therapy with serious adverse outcomes in a cohort of insured patients. Design Case-control study. Data Source Kaiser Permanente Colorado electronic data warehouses and electronic medical records. Patients Cases were patients with a creatine kinase (CK) level of at least 2000 U/L or who developed a clinically significant non–cancer-related blood dyscrasia (thrombocytopenia, neutropenia, leukopenia, aplastic anemia, or pancytopenia) between January 1, 2006, and June 30, 2009 (954 cases). Each case was matched to up to 10 controls by age, sex, and index date (date of the increased CK level or blood dyscrasia–supporting laboratory value). Controls were patients without elevated CK levels or blood dyscrasias who had a routine health maintenance examination during the same time period (index date was the date of their health maintenance examination [9007 controls]). Measurements and Main Results The primary study outcome was colchicine exposure, defined as a colchicine prescription purchase in the 100 days before the index date. The likelihood of colchicine exposure was examined with conditional logistic regression. Cases experienced a higher rate of previous colchicine exposure compared with controls (0.6% vs 0.2%, odds ratio 3.9, 95% confidence interval 1.4–10.7). In addition, cases had higher hospitalization rates (14.9% vs 5.0%, p<0.001), higher mean chronic disease scores (2.5 vs 0.0, p<0.001), and were more likely to have been exposed to drugs that may increase the risk of adverse events due to an interaction with a CYP3A4 inhibitor drug (6.9% vs 2.3%, p<0.001). Conclusion Patients with confirmed elevations in CK level and/or blood dyscrasias had a higher rate of previous colchicine exposure, although low overall, and greater hospitalization rates and exposure to drugs that may increase the risk of adverse events compared with controls. These findings support the 2009 United States Food and Drug Administration labeling for the first branded colchicine product, cautioning use in patients with liver impairment or renal dysfunction and/or those receiving concurrent drugs that may increase risk of adverse events." @default.
• W1978293971 created "2016-06-24" @default.
• W1978293971 creator A5016868811 @default.
• W1978293971 creator A5017536590 @default.
• W1978293971 creator A5037856840 @default.
• W1978293971 creator A5041756887 @default.
• W1978293971 creator A5066131459 @default.
• W1978293971 creator A5072684973 @default.
• W1978293971 creator A5087901835 @default.
• W1978293971 date "2012-09-27" @default.
• W1978293971 modified "2023-10-16" @default.
• W1978293971 title "Assessment of the Association Between Colchicine Therapy and Serious Adverse Events" @default.
• W1978293971 cites W1966408965 @default.
• W1978293971 cites W1967152930 @default.
• W1978293971 cites W1968826806 @default.
• W1978293971 cites W1977980082 @default.
• W1978293971 cites W1982815879 @default.
• W1978293971 cites W1983601208 @default.
• W1978293971 cites W1987061419 @default.
• W1978293971 cites W1993922049 @default.
• W1978293971 cites W2002474041 @default.
• W1978293971 cites W2016390109 @default.
• W1978293971 cites W2023155899 @default.
• W1978293971 cites W2025057167 @default.
• W1978293971 cites W2038078895 @default.
• W1978293971 cites W2039529950 @default.
• W1978293971 cites W2074260890 @default.
• W1978293971 cites W2074608523 @default.
• W1978293971 cites W2085796892 @default.
• W1978293971 cites W2127858748 @default.
• W1978293971 cites W2130198523 @default.
• W1978293971 cites W2131892447 @default.
• W1978293971 cites W2144750464 @default.
• W1978293971 cites W2152306866 @default.
• W1978293971 cites W2157075977 @default.
• W1978293971 cites W2160679764 @default.
• W1978293971 cites W2161968206 @default.
• W1978293971 cites W2166298140 @default.
• W1978293971 cites W2166304177 @default.
• W1978293971 cites W4251129201 @default.
• W1978293971 doi "https://doi.org/10.1002/phar.1125" @default.
• W1978293971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23019065" @default.
• W1978293971 hasPublicationYear "2012" @default.
• W1978293971 type Work @default.
• W1978293971 sameAs 1978293971 @default.
• W1978293971 citedByCount "17" @default.
• W1978293971 countsByYear W19782939712013 @default.
• W1978293971 countsByYear W19782939712014 @default.
• W1978293971 countsByYear W19782939712015 @default.
• W1978293971 countsByYear W19782939712016 @default.
• W1978293971 countsByYear W19782939712020 @default.
• W1978293971 countsByYear W19782939712021 @default.
• W1978293971 countsByYear W19782939712023 @default.
• W1978293971 crossrefType "journal-article" @default.
• W1978293971 hasAuthorship W1978293971A5016868811 @default.
• W1978293971 hasAuthorship W1978293971A5017536590 @default.
• W1978293971 hasAuthorship W1978293971A5037856840 @default.
• W1978293971 hasAuthorship W1978293971A5041756887 @default.
• W1978293971 hasAuthorship W1978293971A5066131459 @default.
• W1978293971 hasAuthorship W1978293971A5072684973 @default.
• W1978293971 hasAuthorship W1978293971A5087901835 @default.
• W1978293971 hasConcept C113775271 @default.
• W1978293971 hasConcept C126322002 @default.
• W1978293971 hasConcept C141071460 @default.
• W1978293971 hasConcept C156957248 @default.
• W1978293971 hasConcept C197934379 @default.
• W1978293971 hasConcept C2776364478 @default.
• W1978293971 hasConcept C2776396001 @default.
• W1978293971 hasConcept C2776694085 @default.
• W1978293971 hasConcept C2777063308 @default.
• W1978293971 hasConcept C2780873365 @default.
• W1978293971 hasConcept C44249647 @default.
• W1978293971 hasConcept C71924100 @default.
• W1978293971 hasConceptScore W1978293971C113775271 @default.
• W1978293971 hasConceptScore W1978293971C126322002 @default.
• W1978293971 hasConceptScore W1978293971C141071460 @default.
• W1978293971 hasConceptScore W1978293971C156957248 @default.
• W1978293971 hasConceptScore W1978293971C197934379 @default.
• W1978293971 hasConceptScore W1978293971C2776364478 @default.
• W1978293971 hasConceptScore W1978293971C2776396001 @default.
• W1978293971 hasConceptScore W1978293971C2776694085 @default.
• W1978293971 hasConceptScore W1978293971C2777063308 @default.
• W1978293971 hasConceptScore W1978293971C2780873365 @default.
• W1978293971 hasConceptScore W1978293971C44249647 @default.
• W1978293971 hasConceptScore W1978293971C71924100 @default.
• W1978293971 hasIssue "11" @default.
• W1978293971 hasLocation W19782939711 @default.
• W1978293971 hasLocation W19782939712 @default.
• W1978293971 hasOpenAccess W1978293971 @default.
• W1978293971 hasPrimaryLocation W19782939711 @default.
• W1978293971 hasRelatedWork W15091867 @default.
• W1978293971 hasRelatedWork W1530620987 @default.
• W1978293971 hasRelatedWork W202648080 @default.
• W1978293971 hasRelatedWork W2152307767 @default.
• W1978293971 hasRelatedWork W2349181903 @default.
• W1978293971 hasRelatedWork W2430901395 @default.
• W1978293971 hasRelatedWork W2994693882 @default.
• W1978293971 hasRelatedWork W2997510975 @default.

• next